PL3967315T3 - Akkermansia muciniphila do leczenia nowotworu złośliwego - Google Patents

Akkermansia muciniphila do leczenia nowotworu złośliwego

Info

Publication number
PL3967315T3
PL3967315T3 PL21189951.3T PL21189951T PL3967315T3 PL 3967315 T3 PL3967315 T3 PL 3967315T3 PL 21189951 T PL21189951 T PL 21189951T PL 3967315 T3 PL3967315 T3 PL 3967315T3
Authority
PL
Poland
Prior art keywords
treating cancer
akkermansia muciniphila
muciniphila
akkermansia
cancer
Prior art date
Application number
PL21189951.3T
Other languages
English (en)
Inventor
Patrice Cani
Amandine EVERARD
Clara BELZER
Willem De Vos
Original Assignee
Université Catholique de Louvain
Wageningen Universiteit
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47257788&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3967315(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Université Catholique de Louvain, Wageningen Universiteit filed Critical Université Catholique de Louvain
Publication of PL3967315T3 publication Critical patent/PL3967315T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
PL21189951.3T 2012-11-19 2013-11-15 Akkermansia muciniphila do leczenia nowotworu złośliwego PL3967315T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2012/073011 WO2014075745A1 (en) 2012-11-19 2012-11-19 Use of akkermansia for treating metabolic disorders

Publications (1)

Publication Number Publication Date
PL3967315T3 true PL3967315T3 (pl) 2025-10-20

Family

ID=47257788

Family Applications (2)

Application Number Title Priority Date Filing Date
PL21154064.6T PL3862010T3 (pl) 2012-11-19 2013-11-15 Zastosowanie akkermansia muciniphila w promowaniu utraty masy ciała
PL21189951.3T PL3967315T3 (pl) 2012-11-19 2013-11-15 Akkermansia muciniphila do leczenia nowotworu złośliwego

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL21154064.6T PL3862010T3 (pl) 2012-11-19 2013-11-15 Zastosowanie akkermansia muciniphila w promowaniu utraty masy ciała

Country Status (14)

Country Link
US (10) US20150306152A1 (pl)
JP (2) JP6426616B2 (pl)
KR (7) KR20250048486A (pl)
CN (2) CN104918626B (pl)
AU (1) AU2013346726B2 (pl)
BR (1) BR112015011403A2 (pl)
CA (1) CA2891758C (pl)
DK (1) DK2919796T3 (pl)
EA (2) EA037315B1 (pl)
ES (3) ES2871817T3 (pl)
MX (1) MX365835B (pl)
PL (2) PL3862010T3 (pl)
PT (1) PT2919796T (pl)
WO (2) WO2014075745A1 (pl)

Families Citing this family (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
IN2014DN07752A (pl) 2012-02-29 2015-05-15 Ethicon Endo Surgery Inc
US10039777B2 (en) 2012-03-20 2018-08-07 Neuro-Lm Sas Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders
WO2014075745A1 (en) * 2012-11-19 2014-05-22 Université Catholique de Louvain Use of akkermansia for treating metabolic disorders
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
JP6637885B2 (ja) 2013-07-21 2020-01-29 ペンデュラム セラピューティクス， インコーポレイテッド マイクロバイオームの特性解明、モニタリング、および処置のための方法およびシステム
US20150246081A1 (en) * 2014-03-03 2015-09-03 Shayne Kenneth Morris Probiotics with methods for growth and use separately and in combination
KR101740893B1 (ko) 2014-05-20 2017-06-13 주식회사 엠디헬스케어 Ａｋｋｅｒｍａｎｓｉａ ｍｕｃｉｎｉｐｈｉｌａ 균에서 유래하는 세포밖 소포를 유효성분으로 함유하는 대사질환의 치료 또는 예방용 조성물
SG10201903823QA (en) 2014-10-31 2019-05-30 Whole Biome Inc Methods and compositions relating to microbial treatment and diagnosis of disorders
WO2016102950A1 (en) 2014-12-23 2016-06-30 4D Pharma Research Limited Immune modulation
SG11201704814SA (en) 2014-12-23 2017-07-28 4D Pharma Res Ltd Pirin polypeptide and immune modulation
PL3292135T3 (pl) 2015-05-06 2023-01-02 Wageningen Universiteit Zastosowanie polipeptydu do wpływania na sygnalizację odpornościową i/lub wpływania na funkcję bariery jelitowej i/lub modulowania stanu metabolicznego
MX383750B (es) 2015-05-06 2025-03-14 Univ Wageningen Método para el cultivo de akkermansia
WO2016203221A1 (en) 2015-06-15 2016-12-22 4D Pharma Research Limited Compositions comprising bacterial strains
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
ME03511B (me) 2015-06-15 2020-04-20 4D Pharma Res Ltd Kompozicije koje sadrže bakterijske sojeve
MA41060B1 (fr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
HRP20191949T1 (hr) 2015-06-15 2020-01-24 4D Pharma Research Limited Blautia stercosis i wexlerae za upotrebu u liječenju upalnih i autoimunih bolesti
CN105106245A (zh) * 2015-08-24 2015-12-02 上海交通大学医学院附属瑞金医院 Akkermansia muciniphila BAA-835菌株的应用
CN105030841A (zh) * 2015-08-24 2015-11-11 上海交通大学医学院附属瑞金医院 Akkermansia muciniphila BAA-835菌株的应用
PT3626081T (pt) * 2015-09-10 2022-02-25 Univ Catholique Louvain Akkermansia pasteurizada para promover a perda de peso
US10537597B2 (en) 2015-10-05 2020-01-21 Schweizerisches Forschungsinstitut Fur Hochgebrigsklima Und Medizin In Davos Use of Akkermansia muciniphila for treating inflammatory conditions
WO2017060491A1 (en) * 2015-10-09 2017-04-13 Biogaia Ab Mucus thickness to prevent diseases
CN105176822B (zh) * 2015-10-23 2019-01-11 广州康泽医疗科技有限公司 一种人类肠道益生菌的优化分离方法
HK1254843B (zh) 2015-11-20 2020-04-17 希杰生物科技株式会社 包含细菌菌株的组合物
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520631D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
EP4257194A3 (en) 2016-02-04 2023-12-20 Universiteit Gent Use of microbial communities for human and animal health
CN115919906A (zh) 2016-03-04 2023-04-07 加利福尼亚大学董事会 微生物聚生体及其用途
SG10201913557TA (en) 2016-03-04 2020-02-27 4D Pharma Plc Compositions comprising bacterial blautia strains for treating visceral hypersensitivity
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
CN109415683B (zh) 2016-04-11 2022-04-15 瓦赫宁恩大学 新细菌物种
GB201609811D0 (en) 2016-06-05 2016-07-20 Snipr Technologies Ltd Methods, cells, systems, arrays, RNA and kits
EP3483256A4 (en) * 2016-07-11 2019-12-04 Korea Research Institute of Bioscience and Biotechnology AKKERMANSIA MUCINIPHILA TRIBE WITH EFFECT FOR PREVENTING OR TREATING DEGENERATIVE BRAIN DISEASES OR METABOLIC DISEASES AND USE THEREOF
TWI802545B (zh) 2016-07-13 2023-05-21 英商４Ｄ製藥有限公司 包含細菌菌株之組合物
EP3498819A4 (en) * 2016-08-12 2020-04-08 BGI Shenzhen FAECALIBACTERIUM BUTYRICIGENERANS AND METHOD FOR BREEDING THEM AND APPLICATION THEREOF
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
AU2017382197B2 (en) 2016-12-20 2022-12-01 The Regents Of The University Of California Compositions and methods for inhibiting seizures
CA3211208A1 (en) 2017-04-03 2018-10-11 Gusto Global, Llc Rational design of microbial-based biotherapeutics
FR3065643B1 (fr) 2017-04-26 2020-04-17 Usines Chimiques D'ivry La Bataille (Ucib) Composition nutraceutique et/ou pharmaceutique pour stimuler la production de beta-defensines de type 2
US10695386B2 (en) 2017-05-11 2020-06-30 Shayne K. Morris Skin microbiome colonizer formulations and methods for use
ES2877726T3 (es) 2017-05-22 2021-11-17 4D Pharma Res Ltd Composiciones que comprenden cepas bacterianas
EP3630942B1 (en) 2017-05-24 2022-11-30 4D Pharma Research Limited Compositions comprising bacterial strain
TWI812624B (zh) 2017-06-14 2023-08-21 南韓商希杰生物科技股份有限公司 包含細菌品系之組成物
ES2841902T3 (es) 2017-06-14 2021-07-12 4D Pharma Res Ltd Composiciones que comprenden cepas bacterianas
PL3600363T3 (pl) 2017-06-14 2021-06-14 4D Pharma Research Limited Kompozycje zawierające szczepy bakteryjne
TWI640314B (zh) * 2017-08-22 2018-11-11 長庚生物科技股份有限公司 戈氏副擬桿菌用於降低胰島素抗性及提升葡萄糖耐受性之用途
TWI636788B (zh) * 2017-08-28 2018-10-01 長庚生物科技股份有限公司 戈氏副擬桿菌用於抑制脂肪肝疾病之用途
CN111372596A (zh) 2017-08-30 2020-07-03 潘德勒姆治疗公司 用于治疗微生物组相关病症的方法和组合物
WO2019092896A1 (ja) * 2017-11-08 2019-05-16 アサヒグループホールディングス株式会社 アッカーマンシア・ムシニフィラ増殖材
BR112020010843A2 (pt) * 2017-11-30 2020-11-10 Glycom A/S oligossacarídeos do leite humano e composições sintéticas desses para modulação da microbiota
RU2020131222A (ru) * 2018-03-02 2022-04-06 Академис Медис Сентрум Фекальный материал для профилактики или лечения аутоиммунных заболеваний
AU2019253714A1 (en) 2018-04-10 2020-11-26 Siolta Therapeutics, Inc. Microbial consortia
US11168299B2 (en) 2018-04-11 2021-11-09 Shayne Morris Pairing probiotics and prebiotics, methods for growth and use, separately and in combination
US11291696B2 (en) 2018-04-11 2022-04-05 Shayne Morris Pairing probiotics and prebiotics, methods for growth and use, separately and in combination
KR102225939B1 (ko) * 2018-04-19 2021-03-10 주식회사 고바이오랩 신규한 Bacteroides vulgatus 균주 및 이를 유효 성분으로 하는 면역 및 대사성 질환 예방 또는 치료용 조성물
CN118638832A (zh) * 2018-05-15 2024-09-13 杜克大学 用于对阿克曼菌进行基因操纵的系统和方法
CN110496140B (zh) * 2018-05-18 2022-05-31 瑞微（深圳）生物科技有限公司 脆弱拟杆菌或阿克曼粘细菌在制备用于预防或治疗肿瘤的药物中的应用
US12292445B2 (en) 2018-05-23 2025-05-06 The Regents Of The University Of California Methods of selecting subjects for treatment with metabolomic modulators
EP3594321A1 (en) * 2018-07-10 2020-01-15 Université catholique de Louvain Dusodibacter, a novel bacterial genus of the gastroinstestinal microbiota and uses thereof
CA3106315A1 (en) 2018-07-19 2020-01-23 Pendulum Therapeutics, Inc. Methods and compositions for microbial engraftment
EP3840761A4 (en) * 2018-08-20 2022-05-18 Murdoch Children's Research Institute BEHAVIORAL TREATMENT
CN110964650B (zh) * 2018-09-27 2022-10-11 上海上药信谊药厂有限公司 一种用于预防和治疗代谢疾病的菌株及其应用
WO2020071660A1 (ko) * 2018-10-01 2020-04-09 한국생명공학연구원 아커만시아 뮤시니필라 균주 또는 이의 배양물을 유효성분으로 함유하는 노화방지용 조성물
KR102197180B1 (ko) * 2018-10-11 2020-12-31 주식회사 고바이오랩 아커만시아 뮤시니필라 균주 및 이를 포함하는 식욕 억제 및 대사성 질환 예방, 개선, 완화 및 치료용 조성물
WO2020076136A2 (ko) * 2018-10-11 2020-04-16 서울대학교산학협력단 아커만시아 뮤시니필라 균주 및 이의 용도
ES2970821T3 (es) * 2018-12-21 2024-05-30 Salomon Amar Uso de Akkermansia en el tratamiento de enfermedades orales
CN114450399A (zh) * 2019-05-02 2022-05-06 卢万天主教大学 用于治疗癌症的乳酸脱氢酶抑制剂多肽
JP7402629B2 (ja) * 2019-07-19 2023-12-21 国立大学法人東京農工大学 プロピオン酸菌発酵物含有組成物
TWI719549B (zh) * 2019-07-22 2021-02-21 大江生醫股份有限公司 促進嗜黏蛋白艾克曼菌生長之益生質組合物
KR102128289B1 (ko) * 2019-08-23 2020-06-30 주식회사 엔테로바이옴 아커만시아 뮤시니필라 eb-amdk27 균주 및 그의 용도
KR102128287B1 (ko) * 2019-08-23 2020-06-30 주식회사 엔테로바이옴 아커만시아 뮤시니필라 eb-amdk19 균주 및 그의 용도
EP4079837A4 (en) * 2019-09-25 2024-06-05 HealthBiome, Inc. OBLIGATE ANAEROBIC HUMAN INTESTINAL MICROBES FOR CANCER TREATMENT AND ITS USE
KR102397916B1 (ko) * 2019-10-01 2022-05-17 (주)헬스바이옴 건강한 임산부 모유 유래 혐기성 인체 균주 및 이를 이용한 대사성 질환의 예방 또는 치료방법
KR20220108765A (ko) 2019-10-07 2022-08-03 시올타 테라퓨틱스, 인크. 치료용 약학 조성물
CN110698547B (zh) * 2019-10-31 2023-01-03 南京农业大学 重组表达的阿克曼菌膜蛋白Amuc_1100及其应用
CN110786376A (zh) * 2019-11-07 2020-02-14 中南大学湘雅医院 嗜黏蛋白艾克曼氏灭活菌在制备酸奶中的应用及酸奶的制备方法和应用
CN111202752A (zh) * 2020-02-17 2020-05-29 上海市内分泌代谢病研究所 阿克曼氏菌组合物
CN111228315A (zh) 2020-02-27 2020-06-05 上海上药信谊药厂有限公司 抗肿瘤组合物
CN111450233B (zh) * 2020-03-19 2021-04-13 中国农业大学 一种微生物代谢产物在缓解糖脂代谢紊乱中的应用
CN115666627A (zh) * 2020-03-25 2023-01-31 韩国生命工学研究院 源自嗜黏蛋白阿克曼菌的tars或其片段，及其用途
EP4125441B1 (en) * 2020-04-03 2026-02-25 International N&H Denmark ApS Composition comprising bacterial strains for improving metabolic health
KR20210131895A (ko) * 2020-04-24 2021-11-03 주식회사 고바이오랩 Glp-1 유도 활성을 갖는 단백질 변이체 및 이의 용도
CN111996267A (zh) * 2020-08-11 2020-11-27 康美华大基因技术有限公司 一种快速检测akk菌的荧光定量pcr引物组、试剂盒及其应用
KR102185827B1 (ko) * 2020-08-26 2020-12-03 주식회사 엔테로바이옴 아커만시아 뮤시니필라 균주를 포함하는 아토피성 질환 예방 또는 치료용 약학적 조성물
BE1028339B1 (fr) * 2020-11-09 2021-12-21 A Mansia Biotech Composition comprenant de l'Akkermansia muciniphila et de l'extrait de thé vert
CN113116936A (zh) * 2021-04-02 2021-07-16 上海市第六人民医院 嗜黏蛋白艾克曼氏菌在制备β-鹅脱氧胆酸抑制剂中的应用
CN113322202B (zh) * 2021-05-31 2022-03-01 君维安(武汉)生命科技有限公司 一种阿克曼氏菌、其培养方法及其应用
KR102380194B1 (ko) * 2021-06-11 2022-03-29 쿼럼바이오 주식회사 갈락토오스를 포함하는 장내 미생물 개체군 개선용 조성물
JP7398714B2 (ja) * 2021-06-28 2023-12-15 東栄新薬株式会社 医療・美容に応用可能なアッカーマンシア・ムシニフィラ増殖促進用組成物およびこれを含む医薬、飲食品、飼料
CN113862193B (zh) * 2021-10-28 2023-12-22 江西普瑞森基因科技有限公司 一株嗜黏蛋白阿克曼氏菌及其在制备抗肿瘤药物中的应用
KR20250083399A (ko) * 2021-11-12 2025-06-10 젤레시스 엘엘씨 장내 마이크로바이옴 조절을 위한 조성물 및 방법
US20250195586A1 (en) * 2022-03-15 2025-06-19 Pendulum Therapeutics, Inc. Novel Microbial Composition and Methods of Use Thereof
CN118638600A (zh) * 2022-03-24 2024-09-13 浙江省农业科学院 具有降血脂作用的益生菌组合物的制备设备
CN114949002B (zh) * 2022-06-08 2024-03-19 广州知易生物科技有限公司 嗜粘蛋白阿克曼菌在制备防治动脉粥样硬化的组合物中的应用
CN115804793B (zh) * 2022-06-08 2025-08-15 石家庄普维生物科技有限公司 嗜粘蛋白阿克曼菌在制备改善酒精性肝功能异常的组合物中的应用、组合物及应用
CN114949003B (zh) * 2022-06-08 2024-03-19 广州知易生物科技有限公司 嗜粘蛋白阿克曼菌及其应用和培养方法
CN115252651B (zh) * 2022-06-08 2024-06-07 广州知易生物科技有限公司 嗜粘蛋白阿克曼菌在制备防治高血压的组合物中的应用和含有其的组合物
CN116115647B (zh) * 2022-06-08 2024-12-20 广州知易生物科技有限公司 嗜粘蛋白阿克曼菌在制备改善代谢综合征的药物组合物或保健品组合物中的应用
CN115463159A (zh) * 2022-09-26 2022-12-13 暨南大学附属第一医院（广州华侨医院） 一种阿克曼菌及阿克曼菌后生元在制备预防或治疗肝脏脂肪病变的药物或保健品中的应用
CN115747357A (zh) * 2022-11-15 2023-03-07 迪辅乐生物(上海)有限公司 肠道嗜粘蛋白-阿克曼氏菌的检测试剂盒及其检测方法
WO2024134035A1 (fr) * 2022-12-22 2024-06-27 Sorbonne Universite Composition et utilisation de turicimonas muris pour le traitement de maladies métaboliques
CN116077536B (zh) * 2023-03-17 2023-11-28 微康益生菌(苏州)股份有限公司 一种用于改善肥胖相关代谢疾病的微生态活菌制剂及其制备方法和应用
CN116999468B (zh) * 2023-08-18 2024-11-15 善恩康生物科技（苏州）有限公司 Akkermansia muciniphila在制备预防、治疗和/或辅助治疗心血管疾病的产品中的应用
AU2024327567A1 (en) * 2023-08-22 2026-01-08 Danisco Usa Inc. Methods and compositions for immune system regulation
JP2025535884A (ja) * 2023-10-12 2025-10-30 レーウェンフック ラボラトリーズ カンパニー リミテッド アッカーマンシアムシニフィラ及び非アルコール性脂肪性肝炎の予防のための使用
CN117603884B (zh) * 2024-01-17 2024-03-26 广州同康生物科技有限公司 一种嗜黏蛋白阿克曼氏菌菌粉及其制备方法
CN118178476A (zh) * 2024-04-03 2024-06-14 暨南大学附属第一医院（广州华侨医院） 阿克曼菌及其制剂在制备促进排便、排脂、减少肠道脂肪吸收的药物中的应用
CN118207140B (zh) * 2024-05-20 2024-09-17 微康益生菌(苏州)股份有限公司 一种具有调节血糖血脂功效的嗜粘蛋白阿克曼氏菌Akk11及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2102350A4 (en) 2006-12-18 2012-08-08 Univ St Louis DARMMICROBIOMA AS A BIOMARKER AND THERAPEUTIC OBJECT FOR THE TREATMENT OF ADIPOSITAS OR ADIPOSITASCONDUCTIVE DISEASES
EP2030623A1 (en) * 2007-08-17 2009-03-04 Nestec S.A. Preventing and/or treating metabolic disorders by modulating the amount of enterobacteria
EP2103226A1 (en) * 2008-03-18 2009-09-23 Friesland Brands B.V. Long-life probiotic food product
CN102939391A (zh) 2010-03-01 2013-02-20 国家农艺研究院 炎症性肠病的诊断方法
IN2014DN07752A (pl) * 2012-02-29 2015-05-15 Ethicon Endo Surgery Inc
WO2014075745A1 (en) * 2012-11-19 2014-05-22 Université Catholique de Louvain Use of akkermansia for treating metabolic disorders

Also Published As

Publication number Publication date
KR20240137696A (ko) 2024-09-20
EA201500535A1 (ru) 2016-03-31
KR102581171B1 (ko) 2023-09-21
US20200237833A1 (en) 2020-07-30
HK1215375A1 (zh) 2016-08-26
EA202100040A3 (ru) 2021-10-29
US20210322489A1 (en) 2021-10-21
JP2016503418A (ja) 2016-02-04
PL3862010T3 (pl) 2025-08-25
KR20210111871A (ko) 2021-09-13
MX365835B (es) 2019-06-17
JP6426616B2 (ja) 2018-11-21
ES3038019T3 (en) 2025-10-08
EA037315B1 (ru) 2021-03-11
KR102297388B1 (ko) 2021-09-03
KR20230080492A (ko) 2023-06-07
PT2919796T (pt) 2021-06-02
CA2891758A1 (en) 2014-05-22
KR20150093711A (ko) 2015-08-18
CN104918626A (zh) 2015-09-16
CN111603488A (zh) 2020-09-01
US20250288622A1 (en) 2025-09-18
KR20250048486A (ko) 2025-04-08
KR20250049431A (ko) 2025-04-11
ES3037446T3 (en) 2025-10-02
CN111603488B (zh) 2024-04-05
MX2015006234A (es) 2015-10-29
WO2014076246A1 (en) 2014-05-22
CN104918626B (zh) 2020-07-07
US20250288621A1 (en) 2025-09-18
ES2871817T3 (es) 2021-11-02
KR20230121938A (ko) 2023-08-21
EA202100040A2 (ru) 2021-06-30
JP2019048825A (ja) 2019-03-28
US20200237832A1 (en) 2020-07-30
KR102297388B9 (ko) 2025-04-01
AU2013346726B2 (en) 2017-11-02
BR112015011403A2 (pt) 2018-02-06
US20210393704A1 (en) 2021-12-23
US20200121737A1 (en) 2020-04-23
AU2013346726A1 (en) 2015-06-04
US20150306152A1 (en) 2015-10-29
US20200155616A1 (en) 2020-05-21
DK2919796T3 (da) 2021-05-31
WO2014075745A1 (en) 2014-05-22
US20190282630A1 (en) 2019-09-19
CA2891758C (en) 2022-06-07

Similar Documents

Publication Publication Date Title
IL288181A (en) Cancer treatment methods
IL272206A (en) Combined treatment for cancer
IL267242B (en) Cancer treatment
PL3967315T3 (pl) Akkermansia muciniphila do leczenia nowotworu złośliwego
PT2925888T (pt) Composições e métodos para tratamento do cancro
IL228644A0 (en) Cancer treatment methods
IL254964A0 (en) A method for treating breast cancer
ZA201503005B (en) Ingenol-derived compounds useful for treating cancer
IL245037A0 (en) Treatment for pancreatic cancer
HUE048625T2 (hu) Módszer rák kezelésére
DK2872176T3 (en) Cancer treatment
EP2934500A4 (en) COMBINATION THERAPY AGAINST CANCER
PL2855475T3 (pl) Alfa-karboliny do leczenia nowotworu
ZA201504169B (en) Anti-adam28 antibody for treating cancer
GB201220901D0 (en) CD44v6-derived peptides for treating pancreatic cancer
GB201222563D0 (en) Cancer treatment
IL239231A0 (en) Combined cancer treatment
AU2012901918A0 (en) Methods for treating cancer